Business
Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, May 23, 2017\n\n\n\nCALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company) today announced that Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics Biotech Inc. will present at the World Immunotherapy Congress USA 2017 in a session on Tuesday, May 23rd, 2017 at 3:20 pm PT. Dr. Gutierrez's presentation will focus on the use of \"REOLYSIN® as potential novel immuno-oncology viral agent for the anti-cancer armamentarium\". The conference takes place on May 23rd and 24th at the Hilton San Diego Resort and Spa in San Diego, CA.\n\n\"As the only company that has evaluated an intravenously-administered oncolytic virus in hundreds of cancer patients, Oncolytics is eager to share our experience with the scientific and clinical communities to support the development of oncolytic viruses for improved patient outcomes,\" said Dr. Gutierrez. \"Our presentation will demonstrate that REOLYSIN is a true immuno-oncology agent that in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. We will address the debate surrounding different clinical endpoints in immuno-oncology studies as we present our emerging safety and positive efficacy data in combination with chemotherapy in breast and pancreatic cancer trials. We are also excited to share our plans for a registration study in metastatic breast cancer, and discuss next generation trials of REOLYSIN in combination with checkpoint inhibitors and IMID's.\" \n\nMore information regarding the presentation is available at: http://www.terrapinn.com/conference/immunotherapy-congress-usa/2017-Agenda.stm\n\nAbout the World Immunotherapy Congress USA Following a successful launch in Europe, World Immunotherapy Congress has added a U.S. event. Co-located with Americas Antibody Congress 2017, World Biosimilar Congress USA, and Cell Culture World Congress USA. World Imm...